Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Four-Factor Prothrombin Complex Concentrate (4F-PCC) Effectively Reverses Rivaroxaban Induced Bleeding in a Rabbit Model of Acute Bleeding

Eva Herzog, PhD, Jochen Mueller-Cohrs, Franz Kaspereit, Wilfried Krege, Peter Niebl, Baerbel Doerr, Stefan Schulte, PhD, Gerhard Dickneite, Prof. PhD

Blood (2014) 124 (21): 4220.

https://doi.org/10.1182/blood.V124.21.4220.4220

Published: 2014

Journal Articles

Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation

Eva Herzog, PhD, Franz Kaspereit, Wilfried Krege, Peter Niebl, Stefan Schulte, PhD, Gerhard Dickneite, Prof. PhD

Blood (2014) 124 (21): 1472.

https://doi.org/10.1182/blood.V124.21.1472.1472

Published: 2014

Journal Articles

Four-Factor Prothrombin Complex Concentrate (4-PCC) Effectively Reverses Edoxaban Induced Bleeding In a Rabbit Model Of Acute Injury

Eva Herzog, PhD, Franz Kaspereit, Wilfried Krege, Ingo Pragst, PhD, Yoshiyuki Morishima, PhD, Stefan Schulte, PhD, Gerhard Dickneite, Prof. PhD

Blood (2013) 122 (21): 1133.

https://doi.org/10.1182/blood.V122.21.1133.1133

Published: 2013

Journal Articles

Pharmacodynamic Activity and Preclinical Safety of CSL362, a Novel Humanised, Affinity Matured Monoclonal Antibody Against Human Interleukin 3 Receptor

Eva Herzog, Samantha Busfield, PhD, Mark Biondo, PhD, Gino Vairo, Mark DeWitte, VMD, Ingo Pragst, Gerhard Dickneite, Prof. PhD, Andrew Nash, PhD, Sabine Zollner

Blood (2012) 120 (21): 1524.

https://doi.org/10.1182/blood.V120.21.1524.1524

Published: 2012

Journal Articles

Pre-Clinical Characteristics of a Recombinant Fusion Protein Linking Activated Coagulation Factor VII with Albumin (rVIIa-FP)

Sabine Zollner, Daniel Schuermann, Elmar Raquet, Jochen Mueller-Cohrs, Thomas Weimer, Ingo Pragst, Gerhard Dickneite, Prof. PhD, Stefan Schulte, PhD

Blood (2012) 120 (21): 1115.

https://doi.org/10.1182/blood.V120.21.1115.1115

Published: 2012

NARROW

Four-Factor Prothrombin Complex Concentrate (4F-PCC) Effectively Reverses Rivaroxaban Induced Bleeding in a Rabbit Model of Acute Bleeding

Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation

Four-Factor Prothrombin Complex Concentrate (4-PCC) Effectively Reverses Edoxaban Induced Bleeding In a Rabbit Model Of Acute Injury

Pharmacodynamic Activity and Preclinical Safety of CSL362, a Novel Humanised, Affinity Matured Monoclonal Antibody Against Human Interleukin 3 Receptor

Pre-Clinical Characteristics of a Recombinant Fusion Protein Linking Activated Coagulation Factor VII with Albumin (rVIIa-FP)

Email alerts

ASH Publications

American Society of Hematology

Four-Factor Prothrombin Complex Concentrate (4F-PCC) Effectively Reverses Rivaroxaban Induced Bleeding in a Rabbit Model of Acute Bleeding

Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation

Four-Factor Prothrombin Complex Concentrate (4-PCC) Effectively Reverses Edoxaban Induced Bleeding In a Rabbit Model Of Acute Injury

Pharmacodynamic Activity and Preclinical Safety of CSL362, a Novel Humanised, Affinity Matured Monoclonal Antibody Against Human Interleukin 3 Receptor

Pre-Clinical Characteristics of a Recombinant Fusion Protein Linking Activated Coagulation Factor VII with Albumin (rVIIa-FP)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only